Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Takes $2.1bn Impairment
Executive Summary
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
You may also be interested in...
Novartis’s Peanut Allergy Setback Perks Up Rivals
Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Nestlé Health Science Refocuses As It Drops Peanut Allergy Treatment
VMS, active nutrition and medical nutrition will be Nestle Health Science's main focus areas going forward with the business looking to offload peanut allergy treatment Palforzia. The Swiss firm announced the move as it reported organic growth of 4% at Health Science for 2022.